Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

P&G Throws Weight Behind Consumer Growth After Shedding Pharma

This article was originally published in The Pink Sheet Daily

Executive Summary

Since many of its key consumer product lines are already mature U.S. brands, Procter & Gamble will have to drive growth by expanding into new markets and acquiring either hard-to-find licenses for OTC switch candidates or existing nonprescription brands.

You may also be interested in...



Teva Stakes OTC Claim With P&G Joint Venture

Teva is making a big push into OTCs, announcing a joint venture with Procter & Gamble to combine OTC businesses outside North America.

Teva Stakes OTC Claim With P&G Joint Venture

Teva is making a big push into OTCs, announcing a joint venture with Procter & Gamble to combine OTC businesses outside North America.

Back In The Game: One Year After Rx Exit, P&G Signs On To Promote Silenor

Somaxon and P&G are preparing to launch the insomnia drug in September with a combined sales force of 215 reps.

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS070000

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel